Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction

Abstract Beraprost sodium (BPS, an analogue of prostacyclin) and telmisartan (TS, an angiotensin receptor blocker) have been reported to have a preventive effect on arterial stiffness in patients with cardiovascular diseases. The purpose of this study was to estimate the effects of a combined therap...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Prostaglandins, leukotrienes and essential fatty acids leukotrienes and essential fatty acids, 2007-06, Vol.76 (6), p.309-314
Hauptverfasser: Nakayama, Tomohiro, Masubuchi, Yuichi, Kawauchi, Kazunori, Masaki, Riko, Hironaga, Takashi, Ishima, Hatsue, Torigoe, Mami, Shimabukuro, Hiroaki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 314
container_issue 6
container_start_page 309
container_title Prostaglandins, leukotrienes and essential fatty acids
container_volume 76
creator Nakayama, Tomohiro
Masubuchi, Yuichi
Kawauchi, Kazunori
Masaki, Riko
Hironaga, Takashi
Ishima, Hatsue
Torigoe, Mami
Shimabukuro, Hiroaki
description Abstract Beraprost sodium (BPS, an analogue of prostacyclin) and telmisartan (TS, an angiotensin receptor blocker) have been reported to have a preventive effect on arterial stiffness in patients with cardiovascular diseases. The purpose of this study was to estimate the effects of a combined therapy using BPS and TS on arterial pulse wave velocity (PWV) values in elderly patients with hypertension and cerebral infarction. Over a 3-month period, 80 subjects with hypertension and histories of cerebral infarction received BPS only (120 μg/day p.o.), TS only (40 mg/day p.o.), both BPS and TS, or no medication at all (control). Arterial PWV and ankle brachial indices (ABI) were determined prior to and after 3 months of drug administration. During the follow-up, there were no significant changes in any of the parameters monitored with the exception of a significant decrease in systolic blood pressure in the BPS only, TS only, and BPS plus TS groups when compared to controls. The difference values for PWV in the control group, BPS only group, TS only group, and BPS plus TS group were +232.5, −114.6, −151.5, and −248.1 cm/s, respectively. The reduction values were significantly more pronounced in the BPS plus TS group than in the BPS only ( P =0.037) and the TS only ( P =0.022) groups. When BPS is combined with TS, an overall additive effect is seen in the improvement of PWV in Japanese patients with hypertension and cerebral infarction. This combination therapy is more beneficial than the corresponding monotherapies.
doi_str_mv 10.1016/j.plefa.2007.05.004
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68101230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0952327807000695</els_id><sourcerecordid>68101230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-fc26879a83861e091c316b9ce148ce3e7ac185c84e5a1501514b3af88f49878f3</originalsourceid><addsrcrecordid>eNqFkkuLFDEUhQtRnJ7RXyBINrqrMo96pBYK4zA-YMCFug6p1A2dNpUqk9RI_yN_prfshgE3rgLJd06Sc25RvGC0YpS1bw7V4sHqilPaVbSpKK0fFTvWCF5yycXjYkf7hpeCd_KiuEzpQCnljNVPiwvWtaytG74rfr-HANYZpz0Ba8FkMlsyQNRLnFMmaR7dOpHFr4lk8JNLOmYdiAsk74EsEe4hZDeHTYZHEDenlJ21AVIiI577eZkQ2jTgR4j-SBadHW4l8svlPdkfF0BpSJuPDiMxEGGIaOSC1dFs_s-KJ1b7BM_P61Xx_cPtt5tP5d2Xj59vru9KU9c8l9bwVna9lkK2DGjPjGDt0BtgtTQgoNOGycbIGhrNGsoaVg9CWylt3ctOWnFVvD754v9_rpCywj8b8F4HmNekWonhc0ERFCfQYFApglVLdJOOR8Wo2gpSB_W3ILUVpGijsCBUvTzbr8ME44Pm3AgCr86ATkZ7G3UwLj1wsu86yTvk3p44wDDuHUSVDEZqYHQRW1Tj7P7zkHf_6I13weGVP-AI6TCvMWDOiqnEFVVft1naRol2OEZt34g_TWnI5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68101230</pqid></control><display><type>article</type><title>Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Nakayama, Tomohiro ; Masubuchi, Yuichi ; Kawauchi, Kazunori ; Masaki, Riko ; Hironaga, Takashi ; Ishima, Hatsue ; Torigoe, Mami ; Shimabukuro, Hiroaki</creator><creatorcontrib>Nakayama, Tomohiro ; Masubuchi, Yuichi ; Kawauchi, Kazunori ; Masaki, Riko ; Hironaga, Takashi ; Ishima, Hatsue ; Torigoe, Mami ; Shimabukuro, Hiroaki</creatorcontrib><description>Abstract Beraprost sodium (BPS, an analogue of prostacyclin) and telmisartan (TS, an angiotensin receptor blocker) have been reported to have a preventive effect on arterial stiffness in patients with cardiovascular diseases. The purpose of this study was to estimate the effects of a combined therapy using BPS and TS on arterial pulse wave velocity (PWV) values in elderly patients with hypertension and cerebral infarction. Over a 3-month period, 80 subjects with hypertension and histories of cerebral infarction received BPS only (120 μg/day p.o.), TS only (40 mg/day p.o.), both BPS and TS, or no medication at all (control). Arterial PWV and ankle brachial indices (ABI) were determined prior to and after 3 months of drug administration. During the follow-up, there were no significant changes in any of the parameters monitored with the exception of a significant decrease in systolic blood pressure in the BPS only, TS only, and BPS plus TS groups when compared to controls. The difference values for PWV in the control group, BPS only group, TS only group, and BPS plus TS group were +232.5, −114.6, −151.5, and −248.1 cm/s, respectively. The reduction values were significantly more pronounced in the BPS plus TS group than in the BPS only ( P =0.037) and the TS only ( P =0.022) groups. When BPS is combined with TS, an overall additive effect is seen in the improvement of PWV in Japanese patients with hypertension and cerebral infarction. This combination therapy is more beneficial than the corresponding monotherapies.</description><identifier>ISSN: 0952-3278</identifier><identifier>EISSN: 1532-2823</identifier><identifier>DOI: 10.1016/j.plefa.2007.05.004</identifier><identifier>PMID: 17616452</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Advanced Basic Science ; Aged ; Aged, 80 and over ; Angiotensin II Type 1 Receptor Blockers - therapeutic use ; Arterial hypertension. Arterial hypotension ; Arteriosclerosis - complications ; Arteriosclerosis - prevention &amp; control ; Benzimidazoles - therapeutic use ; Benzoates - therapeutic use ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood Flow Velocity ; Cardiology. Vascular system ; Cerebral Infarction - complications ; Double-Blind Method ; Drug Therapy, Combination ; Endocrinology &amp; Metabolism ; Epoprostenol - analogs &amp; derivatives ; Epoprostenol - therapeutic use ; Experimental diseases ; Female ; Fundamental and applied biological sciences. Psychology ; Humans ; Hypertension - complications ; Male ; Medical sciences ; Neurology ; Platelet Aggregation Inhibitors - therapeutic use ; Treatment Outcome ; Vascular diseases and vascular malformations of the nervous system ; Vertebrates: endocrinology</subject><ispartof>Prostaglandins, leukotrienes and essential fatty acids, 2007-06, Vol.76 (6), p.309-314</ispartof><rights>2007</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-fc26879a83861e091c316b9ce148ce3e7ac185c84e5a1501514b3af88f49878f3</citedby><cites>FETCH-LOGICAL-c442t-fc26879a83861e091c316b9ce148ce3e7ac185c84e5a1501514b3af88f49878f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0952327807000695$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18977827$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17616452$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakayama, Tomohiro</creatorcontrib><creatorcontrib>Masubuchi, Yuichi</creatorcontrib><creatorcontrib>Kawauchi, Kazunori</creatorcontrib><creatorcontrib>Masaki, Riko</creatorcontrib><creatorcontrib>Hironaga, Takashi</creatorcontrib><creatorcontrib>Ishima, Hatsue</creatorcontrib><creatorcontrib>Torigoe, Mami</creatorcontrib><creatorcontrib>Shimabukuro, Hiroaki</creatorcontrib><title>Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction</title><title>Prostaglandins, leukotrienes and essential fatty acids</title><addtitle>Prostaglandins Leukot Essent Fatty Acids</addtitle><description>Abstract Beraprost sodium (BPS, an analogue of prostacyclin) and telmisartan (TS, an angiotensin receptor blocker) have been reported to have a preventive effect on arterial stiffness in patients with cardiovascular diseases. The purpose of this study was to estimate the effects of a combined therapy using BPS and TS on arterial pulse wave velocity (PWV) values in elderly patients with hypertension and cerebral infarction. Over a 3-month period, 80 subjects with hypertension and histories of cerebral infarction received BPS only (120 μg/day p.o.), TS only (40 mg/day p.o.), both BPS and TS, or no medication at all (control). Arterial PWV and ankle brachial indices (ABI) were determined prior to and after 3 months of drug administration. During the follow-up, there were no significant changes in any of the parameters monitored with the exception of a significant decrease in systolic blood pressure in the BPS only, TS only, and BPS plus TS groups when compared to controls. The difference values for PWV in the control group, BPS only group, TS only group, and BPS plus TS group were +232.5, −114.6, −151.5, and −248.1 cm/s, respectively. The reduction values were significantly more pronounced in the BPS plus TS group than in the BPS only ( P =0.037) and the TS only ( P =0.022) groups. When BPS is combined with TS, an overall additive effect is seen in the improvement of PWV in Japanese patients with hypertension and cerebral infarction. This combination therapy is more beneficial than the corresponding monotherapies.</description><subject>Advanced Basic Science</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiotensin II Type 1 Receptor Blockers - therapeutic use</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Arteriosclerosis - complications</subject><subject>Arteriosclerosis - prevention &amp; control</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Benzoates - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood Flow Velocity</subject><subject>Cardiology. Vascular system</subject><subject>Cerebral Infarction - complications</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Endocrinology &amp; Metabolism</subject><subject>Epoprostenol - analogs &amp; derivatives</subject><subject>Epoprostenol - therapeutic use</subject><subject>Experimental diseases</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Hypertension - complications</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neurology</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><subject>Vertebrates: endocrinology</subject><issn>0952-3278</issn><issn>1532-2823</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkkuLFDEUhQtRnJ7RXyBINrqrMo96pBYK4zA-YMCFug6p1A2dNpUqk9RI_yN_prfshgE3rgLJd06Sc25RvGC0YpS1bw7V4sHqilPaVbSpKK0fFTvWCF5yycXjYkf7hpeCd_KiuEzpQCnljNVPiwvWtaytG74rfr-HANYZpz0Ba8FkMlsyQNRLnFMmaR7dOpHFr4lk8JNLOmYdiAsk74EsEe4hZDeHTYZHEDenlJ21AVIiI577eZkQ2jTgR4j-SBadHW4l8svlPdkfF0BpSJuPDiMxEGGIaOSC1dFs_s-KJ1b7BM_P61Xx_cPtt5tP5d2Xj59vru9KU9c8l9bwVna9lkK2DGjPjGDt0BtgtTQgoNOGycbIGhrNGsoaVg9CWylt3ctOWnFVvD754v9_rpCywj8b8F4HmNekWonhc0ERFCfQYFApglVLdJOOR8Wo2gpSB_W3ILUVpGijsCBUvTzbr8ME44Pm3AgCr86ATkZ7G3UwLj1wsu86yTvk3p44wDDuHUSVDEZqYHQRW1Tj7P7zkHf_6I13weGVP-AI6TCvMWDOiqnEFVVft1naRol2OEZt34g_TWnI5g</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>Nakayama, Tomohiro</creator><creator>Masubuchi, Yuichi</creator><creator>Kawauchi, Kazunori</creator><creator>Masaki, Riko</creator><creator>Hironaga, Takashi</creator><creator>Ishima, Hatsue</creator><creator>Torigoe, Mami</creator><creator>Shimabukuro, Hiroaki</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070601</creationdate><title>Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction</title><author>Nakayama, Tomohiro ; Masubuchi, Yuichi ; Kawauchi, Kazunori ; Masaki, Riko ; Hironaga, Takashi ; Ishima, Hatsue ; Torigoe, Mami ; Shimabukuro, Hiroaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-fc26879a83861e091c316b9ce148ce3e7ac185c84e5a1501514b3af88f49878f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Advanced Basic Science</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiotensin II Type 1 Receptor Blockers - therapeutic use</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Arteriosclerosis - complications</topic><topic>Arteriosclerosis - prevention &amp; control</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Benzoates - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood Flow Velocity</topic><topic>Cardiology. Vascular system</topic><topic>Cerebral Infarction - complications</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Endocrinology &amp; Metabolism</topic><topic>Epoprostenol - analogs &amp; derivatives</topic><topic>Epoprostenol - therapeutic use</topic><topic>Experimental diseases</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Hypertension - complications</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neurology</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakayama, Tomohiro</creatorcontrib><creatorcontrib>Masubuchi, Yuichi</creatorcontrib><creatorcontrib>Kawauchi, Kazunori</creatorcontrib><creatorcontrib>Masaki, Riko</creatorcontrib><creatorcontrib>Hironaga, Takashi</creatorcontrib><creatorcontrib>Ishima, Hatsue</creatorcontrib><creatorcontrib>Torigoe, Mami</creatorcontrib><creatorcontrib>Shimabukuro, Hiroaki</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Prostaglandins, leukotrienes and essential fatty acids</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakayama, Tomohiro</au><au>Masubuchi, Yuichi</au><au>Kawauchi, Kazunori</au><au>Masaki, Riko</au><au>Hironaga, Takashi</au><au>Ishima, Hatsue</au><au>Torigoe, Mami</au><au>Shimabukuro, Hiroaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction</atitle><jtitle>Prostaglandins, leukotrienes and essential fatty acids</jtitle><addtitle>Prostaglandins Leukot Essent Fatty Acids</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>76</volume><issue>6</issue><spage>309</spage><epage>314</epage><pages>309-314</pages><issn>0952-3278</issn><eissn>1532-2823</eissn><abstract>Abstract Beraprost sodium (BPS, an analogue of prostacyclin) and telmisartan (TS, an angiotensin receptor blocker) have been reported to have a preventive effect on arterial stiffness in patients with cardiovascular diseases. The purpose of this study was to estimate the effects of a combined therapy using BPS and TS on arterial pulse wave velocity (PWV) values in elderly patients with hypertension and cerebral infarction. Over a 3-month period, 80 subjects with hypertension and histories of cerebral infarction received BPS only (120 μg/day p.o.), TS only (40 mg/day p.o.), both BPS and TS, or no medication at all (control). Arterial PWV and ankle brachial indices (ABI) were determined prior to and after 3 months of drug administration. During the follow-up, there were no significant changes in any of the parameters monitored with the exception of a significant decrease in systolic blood pressure in the BPS only, TS only, and BPS plus TS groups when compared to controls. The difference values for PWV in the control group, BPS only group, TS only group, and BPS plus TS group were +232.5, −114.6, −151.5, and −248.1 cm/s, respectively. The reduction values were significantly more pronounced in the BPS plus TS group than in the BPS only ( P =0.037) and the TS only ( P =0.022) groups. When BPS is combined with TS, an overall additive effect is seen in the improvement of PWV in Japanese patients with hypertension and cerebral infarction. This combination therapy is more beneficial than the corresponding monotherapies.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>17616452</pmid><doi>10.1016/j.plefa.2007.05.004</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0952-3278
ispartof Prostaglandins, leukotrienes and essential fatty acids, 2007-06, Vol.76 (6), p.309-314
issn 0952-3278
1532-2823
language eng
recordid cdi_proquest_miscellaneous_68101230
source MEDLINE; Elsevier ScienceDirect Journals
subjects Advanced Basic Science
Aged
Aged, 80 and over
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Arterial hypertension. Arterial hypotension
Arteriosclerosis - complications
Arteriosclerosis - prevention & control
Benzimidazoles - therapeutic use
Benzoates - therapeutic use
Biological and medical sciences
Blood and lymphatic vessels
Blood Flow Velocity
Cardiology. Vascular system
Cerebral Infarction - complications
Double-Blind Method
Drug Therapy, Combination
Endocrinology & Metabolism
Epoprostenol - analogs & derivatives
Epoprostenol - therapeutic use
Experimental diseases
Female
Fundamental and applied biological sciences. Psychology
Humans
Hypertension - complications
Male
Medical sciences
Neurology
Platelet Aggregation Inhibitors - therapeutic use
Treatment Outcome
Vascular diseases and vascular malformations of the nervous system
Vertebrates: endocrinology
title Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T05%3A04%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beneficial%20effect%20of%20beraprost%20sodium%20plus%20telmisartan%20in%20the%20prevention%20of%20arterial%20stiffness%20development%20in%20elderly%20patients%20with%20hypertension%20and%20cerebral%20infarction&rft.jtitle=Prostaglandins,%20leukotrienes%20and%20essential%20fatty%20acids&rft.au=Nakayama,%20Tomohiro&rft.date=2007-06-01&rft.volume=76&rft.issue=6&rft.spage=309&rft.epage=314&rft.pages=309-314&rft.issn=0952-3278&rft.eissn=1532-2823&rft_id=info:doi/10.1016/j.plefa.2007.05.004&rft_dat=%3Cproquest_cross%3E68101230%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68101230&rft_id=info:pmid/17616452&rft_els_id=1_s2_0_S0952327807000695&rfr_iscdi=true